Evidence map›Paper›PMID 34272238›Full record

ArticleScience advances2021

Plasmid hypermutation using a targeted artificial DNA replisome.

Xiao Yi, Joleen Khey, Romas J Kazlauskas, Michael Travisano

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. CRISPR-DNA Polymerase Assisted Targeted Mutagenesis for Regulable Laboratory Evolution.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. In vivo hypermutation and continuous evolution.Nature reviews. Methods primers · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xiao YiBioTechnology Institute, University of Minnesota, Minneapolis, MN, USA. xy.sysu@gmail.com rjk@umn.edu travisan@umn.edu.ORCID 0000-0003-4025-856X
Joleen KheyDepartment of Plant and Microbial Biology, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-5575-805X
Romas J KazlauskasBioTechnology Institute, University of Minnesota, Minneapolis, MN, USA. xy.sysu@gmail.com rjk@umn.edu travisan@umn.edu.ORCID 0000-0002-3570-2411
Michael TravisanoBioTechnology Institute, University of Minnesota, Minneapolis, MN, USA. xy.sysu@gmail.com rjk@umn.edu travisan@umn.edu.ORCID 0000-0001-8168-0842
University of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extensive exploration of a protein's sequence space for improved or new molecular functions requires in vivo evolution with large populations. But disentangling the evolution of a target protein from the rest of the proteome is challenging. Here, we designed a protein complex of a targeted artificial DNA replisome (TADR) that operates in live cells to processively replicate one strand of a plasmid with errors. It enhanced mutation rates of the target plasmid up to 2.3 × 10

Indexed as

DNA-Directed DNA PolymeraseMultienzyme ComplexesMutagenesisPlasmidsReplisomesDNA-Directed DNA PolymeraseMultienzyme ComplexesReplisomes

Identifiers

PMID34272238
PMCPMC8284885
OpenAlexW3180885712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.